Quick Summary
- Device: Embecta’s new disposable insulin patch pump with a 300-unit reservoir.
- FDA Clearance: Approved as a tubeless insulin delivery system for both Type 1 and Type 2 diabetes.
- Design: Aimed at meeting the higher daily insulin needs of Type 2 diabetes patients.
- Impact: Provides an accessible alternative to multiple daily injections for Type 2 diabetes management.
Embecta has received FDA 510(k) clearance for its innovative disposable insulin patch pump, designed to improve insulin delivery for people with Type 2 diabetes. While many insulin pumps on the market were primarily developed for Type 1 diabetes, this tubeless patch pump includes a 300-unit insulin reservoir, specifically tailored for those with Type 2 diabetes who often require higher daily insulin doses. This system provides adjustable basal and bolus insulin doses for up to three days, offering a viable alternative to the multiple daily injections (MDI) commonly needed for managing Type 2 diabetes.
Meeting the Unique Needs of Type 2 Diabetes Patients
Embecta’s insulin patch pump addresses a significant gap in diabetes care, as most available automated insulin delivery systems were originally designed with Type 1 diabetes patients in mind. The device’s 300-unit insulin reservoir meets the needs of the Type 2 diabetes population, who typically need more insulin per day. A study sponsored by Embecta showed that the 300-unit capacity was sufficient for 64% of Type 2 patients for 72 hours, reducing the frequency of insulin administration and improving convenience.
Designed for ease of use, the system also includes a secure controller with Bluetooth technology and a color touchscreen interface, making it simple for patients to manage their insulin. This patch pump helps reduce the burden of diabetes management, providing a practical solution for those who prefer a more discreet and convenient insulin delivery method.
Impact and Future Plans
As diabetes prevalence continues to rise, particularly Type 2 diabetes, the availability of devices tailored to these patients is critical. Embecta’s patch pump offers an accessible option that may encourage more patients to transition from MDI to a pump, thus improving adherence and long-term health outcomes. The company also plans to develop an automated insulin delivery version of this device, which would further reduce the manual effort required for diabetes management.
CEO Dev Kurdikar emphasized Embecta’s commitment to serving the diabetes community, noting that the patch pump represents “a meaningful step toward a life with fewer diabetes management burdens.” Embecta’s innovation aligns with growing demand for Type 2 diabetes solutions, especially as the global diabetes population is expected to nearly double by 2050.
References
